Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John Lu, MD
Seagen Inc.
Study Director - Zejing Wang, MD, PhD
Seagen Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
260 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site Ar54008
Buenos Aire, Argentina
- Site Ar54011
CABA, Argentina
- Site Ar54005
Córdoba, Argentina
- Site Ar54006
La Rioja, Argentina
- Site Ar54004
Mendoza, Argentina
- Site Ar54001
Rosario, Argentina
- Site Ar54002
San Miguel, Argentina
- Site Ar54012
San Miguel de Tucumán, Argentina
- Site Ar54003
Viedma, Argentina
- Site Au61003
Box Hill, Australia
- Site Aus61001
Douglas, Australia
- Site Aus61004
Heidelberg, Australia
- Site Aus61002
Macquarie Park, Australia
- Site Aus61006
South Australia, Australia
- Site Au61005
South Brisbane, Australia
- Site Be32003
Brussels, Belgium
- Site Be32002
Ghent, Belgium
- Site Be32001
Liège, Belgium
- Site Be32007
Lueven, Belgium
- Site Be32006
Roeselare, Belgium
- Site Ca11004
Calgary, Alberta, Canada
- Site Ca11003
Edmonton, Alberta, Canada
- Site Ca11006
Vancouver, British Columbia, Canada
- Site Ca11002
Hamilton, Ontario, Canada
- Site Ca11009
London, Ontario, Canada
- Site Ca11011
Oshawa, Ontario, Canada
- Site Ca11005
Toronto, Ontario, Canada
- Site Ca11012
Toronto, Ontario, Canada
- Site Ca11001
Montreal, Quebec, Canada
- Site Ca11010
Montreal, Quebec, Canada
- Site Ca11008
Québec, Canada
- Site Cn86001
Beijing, China
- Site Cn86004
Beijing, China
- Site Cn86005
Beijing, China
- Site Cn86009
Beijing, China
- Site Cn86015
Bengbu, China
- Site Cn86003
Changchun, China
- Site Cn86006
Changsha, China
- Site Cn86016
Changsha, China
- Site Cn86010
Chengdu, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Mar 2020
- Primary completion
- 8 Aug 2023
- Completion
- 1 Mar 2028
- Last update posted
- 29 May 2026
- Registered enrollment
- 886
- Registry id
- NCT04223856
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.